Advertisement

November 7, 2022

ACC, AHA Issue Aortic Disease Guideline

November 7, 2022—The American College of Cardiology (ACC) and the American Heart Association (AHA) announced the publication of a new guideline on the diagnosis and management of aortic disease, focusing on surgical intervention considerations, consistent imaging practices, genetic and familial screenings, and the importance of a multidisciplinary aortic team.

“2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the AHA/ACC Joint Committee on Clinical Practice Guidelines” by Eric M. Isselbacher, MD, et al was published simultaneously online in the Journal of the American College of Cardiology and AHA’s journal Circulation.

The guideline will be discussed at 3:00 pm on November 7 during the “Highlights of the New AHA/ACC Aortic Disease Guidelines” session at AHA’s Scientific Sessions 2022 held November 5-7 in Chicago, Illinois.

The guideline was developed in collaboration with and endorsed by the American Association for Thoracic Surgery, American College of Radiology, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, and Society for Vascular Medicine. It was endorsed by the Society of Interventional Radiology and Society for Vascular Surgery.

According to ACC/AHA, this new aortic disease guideline replaces the “2010 ACCF/AHA Guidelines for the Diagnosis and Management of Patients with Thoracic Aortic Disease” and the “2015 Surgery for Aortic Dilation in Patients with Bicuspid Aortic Valves: A Statement of Clarification from the ACC/AHA Task Force on Clinical Practice Guidelines.” It is intended to be used concurrently with the “2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease.”

The new guideline brings together guidelines for both the thoracic and abdominal aorta and is targeted to cardiovascular clinicians who are involved in the care of patients with aortic disease, including general cardiovascular care clinicians and emergency medicine clinicians.

Dr. Isselbacher, the guideline writing committee Chair, commented in the ACC/AHA press release, “There has been a host of new evidence-based research available for clinicians in the past decade when it comes to aortic disease. It was time to re-evaluate and update the previous, existing guidelines. We hope this new guideline can inform clinical practices with up-to-date and synthesized recommendations, targeted toward a full multidisciplinary aortic team working to provide the best possible care for this vulnerable patient population.”

As summarized in the ACC/AHA press release, recommendations in the new guideline include:

  • Family screening: To identify individuals most at risk for aortic disease, the new guideline recommends family screening, including genetic testing and imaging, of first-degree relatives of individuals diagnosed with aneurysms of the aortic root or ascending thoracic aorta, or those with aortic dissection.
  • Consistency in imaging: The guideline stresses the importance of consistency in the way CT or MRI imaging is obtained and reported, in the measurement of aortic size and features and in how often images are used for monitoring before and after repair surgery or other intervention. Ideally, all surveillance imaging for a patient should be done using the same modality and in the same lab.
  • Patient size adjustments: The guideline recommends modifying surgical thresholds in patients who are significantly smaller or taller than average. Guidance for the size of aortic injury that would indicate a need for surgery should be adjusted for the patient’s body surface area or height.
  • Surgery: At institutions with multidisciplinary aortic teams and experienced surgeons, the threshold for surgical intervention for sporadic aortic root and ascending aortic aneurysms has been lowered from 5.5 cm to 5 cm in certain individuals. Risk of aortic aneurysm or dissection increases with size. With this recommendation, select individuals may get lifesaving surgery sooner to prevent death from an aortic aneurysm or dissection. In addition, the guideline updates the definition for rapid aneurysm growth rate; surgery is recommended for individuals with aneurysms of aortic root and ascending thoracic aorta with a confirmed growth rate of ≥ 0.3 cm per year across 2 consecutive years or ≥ 0.5 cm in 1 year. Rapid aortic growth is a risk factor for rupture.
  • Multidisciplinary aortic teams: For individuals who require aortic intervention, outcomes are optimized when surgery is performed by an experienced surgeon working in a multidisciplinary aortic team. The new guideline recommends “a specialized hospital team with expertise in the evaluation and management of aortic disease, in which care is delivered in a comprehensive, multidisciplinary manner.” These teams may consist of cardiac and vascular surgeons with extensive experience managing complex aortic disease at a center with a high volume of aortic interventions; imaging specialists with expertise in aortic disease who can interpret CT, MRI, and echocardiography; anesthesiologists experienced in the management of acute aortic disease and cerebrospinal fluid drainage; and an intensive care unit experienced in the management of acute aortic disease.
  • Shared decision-making: The multidisciplinary aortic team is highly encouraged to involve the patient in decision-making, especially when individuals are on the borderline of thresholds for repair or eligible for different types of surgical repair. Shared decision-making should also be used with individuals who are pregnant or may become pregnant to consider the risks of pregnancy in individuals with aortic disease. Shared decision-making has become increasingly important in patient-centered care and may be especially useful when discussing quality of life, goals of care, and desired procedural outcomes.

Advertisement


November 7, 2022

Medtronic’s Symplicity Spyral RDN System Demonstrates Clinical Benefits in SPYRAL HTN-ON MED Trial

November 6, 2022

ReCor’s Paradise uRDN System Evaluated in Pooled Analysis of RADIANCE Trials